TX HR 307
enrolledCongratulating Dr. Debra Patt on receiving the Physician Advocacy Champion Award from the U.S. Oncology Network.
Texas · 89th Legislature (2025 Regular Session) · lower
Quick answers
Did TX HR 307 pass?
TX HR 307 passed both chambers and was enrolled, but its session adjourned long enough ago that the executive-action window has closed. Bill Commons did not capture the final signature or veto, so the outcome is unknown here — check the TX legislature's own record. Latest recorded action (2025-03-31): Reported enrolled
What is TX HR 307 about?
TX HR 307 is a resolution in the 89th Legislature (2025 Regular Session) titled “Congratulating Dr. Debra Patt on receiving the Physician Advocacy Champion Award from the U.S. Oncology Network.”.
Who sponsors TX HR 307?
Oliverson is the primary sponsor of TX HR 307.
- Introduced
- —
- Latest action
- 2025-03-31 — Reported enrolled
- Bill type
- resolution
- Last updated
- —
Subjects
Sponsors
- Oliversonprimary
Committees
Not provided by source.
Action timeline
2025-02-19
Filed
filing
2025-02-25
Referred to Local & Consent Calendars
referral-committee
2025-03-26
Considered in Local & Consent Calendars
2025-03-28
Placed on Congrat. & Memorial Res. Calendar
2025-03-31
Laid before the House
receipt
2025-03-31
Adopted
passage
2025-03-31
Reported enrolled
enrolled
Versions
Documents
Votes
Not provided by source.
Related bills
No related bills recorded for this bill.
Official source
Attribution
Data from openstates_bulk_csv, retrieved 2026-07-24T05:33:51.767464Z
Inspect retained evidence for changes recorded after evidence tracking began:
Session-wide evidence can include changes to other bills:
Use this data
Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=TX&identifier=HR 307. See the API docs or the MCP server for AI assistants.
Known limitations
- Sponsor party and chamber affiliation are not yet captured by this API.
- Committee referrals are not yet captured.
See the methodology page for data sources and limitations.